Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ark Genomic Revolution ETF (NY: ARKG )

26.23 -0.06 (-0.23%)
Official Closing Price Updated: 8:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,394,356
Open 26.31
Bid (Size) 26.33 (27)
Ask (Size) 26.95 (3)
Prev. Close 26.29
Today's Range 26.05 - 27.48
52wk Range 21.97 - 34.37
Shares Outstanding 518,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Almost Every Ark Fund Is Now Underperforming The Overall Market. Here's Why.
The fund company focuses on the right industries, but these industries' stocks require a very particular economic backdrop and market environment. 
Via The Motley Fool
5 Technology ETFs At The Forefront Of The August Rebound
Here are five technology ETFs that have been leading the way higher over the past week. 
Via Talk Markets
Topics ETFs

Performance

YTD
-19.83%
-19.83%
1 Month
-1.91%
-1.91%
3 Month
+7.94%
+7.94%
6 Month
-9.11%
-9.11%
1 Year
-11.24%
-11.24%

More News

Read More
Cathie Wood Buys $28 Million Of Amazon, Targets Crypto; Sells $26 Million Of This Stock
Via Investor's Business Daily
Cathie Wood-Led Ark Invest Went Shopping For AMD, Tesla, Amazon, Coinbase, Robinhood, Meta And Palantir Shares Amid Market Crash On Monday
Via Benzinga
Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
Via Benzinga
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
Via Benzinga
Topics ETFs
Why Ginkgo Bioworks Stock Is Sinking Today
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Via The Motley Fool
Here's How Cathie Wood (Almost) Completely Missed the Boat on Artificial Intelligence (AI) -- and the Simplest Way You Can Avoid Making the Same Mistake
Via The Motley Fool
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Cathie Wood Has Been Steadily Selling Shares of This Growth Stock. Should You?
Via The Motley Fool
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
Via Benzinga
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
Via The Motley Fool
Cathie Wood's Ark Invest Scoops Up Shares Of AMD And Palantir — Dumps Moderna Stock Worth $4.4M
Via Benzinga
Investment Advisor Says 'Throwing Random Darts At Tickers' Would Beat ARKK As Cathie Wood's Flagship Fund Lags Far Behind Soaring Market: 'How Do They Do It?!'
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update
Via Benzinga
Cathie Wood's Ark Empire Bleeds As Investor Outflows Spike: 'The Loyal Shareholders Have Become Frustrated'
Via Benzinga
Topics ETFs
3 Cathie Wood ETFs Just Hit 4-Month Lows. Are They Worth Buying Now?
Via The Motley Fool
Topics ETFs
Cathie Wood's Ark Invest Continues To Shed Coinbase, Nvidia Shares
Via Benzinga
Cathie Wood's Ark Buys Roku, Palantir And $1M Worth Of Stock In This Healthcare Company
Via Benzinga
Cathie Wood's Ark Sheds Nearly $4M Nvidia Shares And Trims Position In This AI Peer
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Invest Continues To Double Down On Moderna, Sells Nvidia Shares
Via Benzinga
Cathie Wood's Ark Takes Profits In Rallying Crypto Stocks, Trims Nvidia And This COVID-19 Play Further
Via Benzinga
Topics ETFs
Exposures COVID-19
Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?
Via The Motley Fool
5 Technologies That Could Be Worth $220 Trillion By 2030, Cathie Wood's ARK Predicts: 'The Time Is Now'
Via Benzinga
Is Cathie Wood Buying The Rumor? Ark More Than Doubles Stake In This COVID-19 Vaccine Maker Ahead Of Flurry Of Catalysts
Via Benzinga
Topics ETFs
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.